Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of Biological Therapy in Severe Asthma: Where We Are?
Lorenzo Carriera, Marta Fantò, Alessia Martini, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 11, pp. 1594-1594
Open Access | Times Cited: 10

Showing 10 citing articles:

Precision medicine for severe asthma – Biological targeted therapy
Bingqing Sun, Kunlu Shen, Ruiheng Zhao, et al.
International Immunopharmacology (2024) Vol. 134, pp. 112189-112189
Open Access | Times Cited: 5
Biologics in severe asthma: a state-of-the-art review
Bishal Gyawali, Steve N. Georas, Sandhya Khurana
European Respiratory Review (2025) Vol. 34, Iss. 175, pp. 240088-240088
Open Access
Combining Dual Biologics Therapy for Severe Asthma: A Series of Ten Cases
Y.-C. Chen, Lu Wang, Jiaxing Xie
Journal of Asthma and Allergy (2025) Vol. Volume 18, pp. 507-517
Open Access
Inflammatory and homeostatic roles of eosinophil subpopulations in chronic rhinosinusitis with nasal polyp pathogenesis
Kantapat Simmalee, Putthapoom Lumjiaktase, Theerasuk Kawamatawong, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Personalized Medicine in Severe Asthma: From Biomarkers to Biologics
Chun‐Yu Chen, Kang‐Hsi Wu, Bei-Cyuan Guo, et al.
International Journal of Molecular Sciences (2023) Vol. 25, Iss. 1, pp. 182-182
Open Access | Times Cited: 9
Biologic therapy in rare eosinophil-associated disorders: remaining questions and translational research opportunities
Paneez Khoury, Florence Roufosse, Fei Li Kuang, et al.
Journal of Leukocyte Biology (2024)
Open Access | Times Cited: 3
Cost-effectiveness of mepolizumab for severe eosinophilic asthma in China
Xiong Chaogang, An Mengna, Zhen Wang, et al.
Journal of Asthma (2024) Vol. 61, Iss. 9, pp. 1068-1075
Closed Access | Times Cited: 1
Asthma loss of control after switch from anti-IL-5/5R drugs to dupilumab in severe eosinophilic asthma: A case series
Camille Poisson, Cécile Chenivesse, E. Cuvillon, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024) Vol. 12, Iss. 7, pp. 1914-1917
Closed Access | Times Cited: 1
Precision medicine to personalize medicine in allergic airway disease
Jean Kim
Current Opinion in Allergy and Clinical Immunology (2024) Vol. 24, Iss. 3, pp. 109-113
Closed Access
Phenotypes and endotypes in asthma-practical approach
P.C. Kathuria, Manisha Rai
Indian Journal of Allergy Asthma and Immunology (2024) Vol. 38, Iss. 1, pp. 3-12
Open Access
Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency
Xiaojuan Ma, Shuang Zhang, Xiaochen Ren, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Combination treatment with monoclonal antibodies for the management of severe asthma and immune-mediated inflammatory diseases: a comprehensive review
Lorenzo Carriera, Sara Caporuscio, Marta Fantò, et al.
Monaldi Archives for Chest Disease (2024)
Open Access
Page 1

Scroll to top